Including biomarkers early on in the drug development process can make use of genomic and proteomic techniques, thereby increasing the probability that initial administration to humans will be safe, or help determine the relevance of animal findings in humans. In a clinical environment, such information can be used to exclude participants from trials, or monitor reactions to drugs in participants who may be at risk from a treatment.

Join our experts at the 14^th WRIB Virtual from June 15-29 to learn more about Altasciences' list of biomarkers and to understand how our integrated biomarker approach from preclinical to clinical can enhance the safety of new drugs, improve the assessment of promising drug candidates, as well as reduce the cost of developing drugs and bringing them to market.

Discover how Altasciences delivers comprehensive bioanalytical solutions through all phases of your drug development journey. Using the latest technologies and scientific know-how, we bring your vision to life.

As an alternative to traditional venipuncture, blood microsampling represents a less invasive and simplified collection technique, resulting in numerous benefits for preclinical and clinical studies alike. Recent advances in device technology, specifically the Mitra® VAMS® microsampler manufactured by Neoteryx, has enabled Altasciences to fully support blood microsampling programs.

With over 12 Mitra® VAMS® assays validated for a range of drug applications and study types, we look forward to sharing our combined expertise in support of your next microsampling program.